The different invasion capacities and cell morphologies 16 days after treatment of BLM melanoma cells and the induction of invasive growth in the RGP SBCL2 cells after BMP-2 and nodal treatment confirm a temporary inhibitory influence of the antagonists and an enhancing impact of the agonists on invasion in this in vitro skin model. The gene discussed is BMP2; the disease is melanoma.